Recent Finacing
Recent Raise
Adlai Nortye Biopharma is a Hangzhou-based clinical-stage biopharmaceutical company developing immuno-oncology therapies, advancing a >10-product pipeline including Reolysin (IV oncolytic virus, Phase III-ready) and AN0025 (EP4 antagonist, Phase Ib).
